With Sienna's first IVD (hTERT test) launched, the focus is market penetration, geographical expansion and application expansion for that product, as well as the addition of new technology to the pipeline which includes the commercialisation of recently acquired NETs technology.

About Sienna Cancer Diagnostics

Sienna Cancer Diagnostics Ltd. is a public listed company, with global operations based in Melbourne, Victoria. Head office and laboratories are located within the Small Technologies Cluster (STC), a successful and thriving environment where a number of biotechnology and other high technology businesses have their research and development, commercialisation and manufacturing operations.

Sienna’s strengths lie in identifying novel technologies then developing and commercialising them to satisfy an unmet clinical / market need. The team has proven skills and experience in navigating all elements of this complex pathway. This includes developing test formats that fit existing clinical paradigms and pathology workflows, utilising existing automation equipment, accessing existing reimbursement pathways, and optimising regulatory strategies, all focussed on getting our product to the broadest possible market in the most timely and cost efficient manner.


Sienna is creating a portfolio of unique and clinically useful tests for the pathology diagnostics market. The pipeline being established will create significant opportunity for the company, and allow sustainable revenue and profit growth through the delivery of meaningful products that add real value to the delivery of cancer healthcare.


Sienna’s focus is the development and commercialisation of innovative tests for use in clinical diagnostic laboratories worldwide.

Key Facts about Sienna

  • Public listed company (ASX:SDX), with global operations based in Melbourne, Victoria
  • Delivering value-adding products to the pathology diagnostics market
  • Experienced development and commercialisation team
  • Commercial sales of first IVD product have started

Sign up for updates